Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer
Yuqing Zhang, Courtney W. Houchen, Min Li
Abstract
The patient-derived organoids (PDO) platform recapitulates the phenotype, genotype, and molecular characteristics of primary tumors. High-throughput drug screening in terms of pharmacotyping using standard-of-care chemotherapy agents in the PDO platform has shown promising sensitivities to guide precision medicine for individual patients with pancreatic ductal adenocarcinoma (PDAC) within a clinically relevant time frame. See related article by Seppälä et al., p. 3296.
Topics & Concepts
OrganoidPancreatic ductal adenocarcinomaPrecision medicinePancreatic cancerMedicineOncologyAdenocarcinomaInternal medicineCancerPathologyBiologyNeurosciencePancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsCancer Cells and Metastasis